Medicinal Chemistry
News and Events - 2010


Professor Edmond LaVoie was reappointed as Department Chair.  This appointment will be effective until June 30, 2013.

Professor Longqin Hu served on the SBIR review panel for the National Institutes of Health, Bethesda, MD, March 24-26, 2010.
Patents Filed by Professor Edmond LaVoie:
PCT Application US2010/033439 Therapeutic Compounds
PCT Application US2010/033431 Therapeutic Compounds
PCT Application US2010/026381 Therapeutic Compounds
PCT Application US2010/033278 Antimicrobial Agents

Rzuczek, S. G., Pilch, D. S., Liu, A., Liu, L. F., LaVoie, E. J., and Rice, J. E., Macrocyclic pyridyl polyoxazoles:  Selective RNA and DNA G-quadruplex ligands as antitumor agents. J. Med. Chem., 53, 3632-3644, 2010.

Satyanarayana, M., Kim, Y-A., Rzuczek, S. G., Pilch, D. S., Liu, A. A., Liu, L. F., Rice, J. E., and LaVoie, E. J., Macrocyclic hexaoxazoles: Influence of aminoalkyl substituents on RNA and DNA G-quadruplex stabilization and cytotoxicity. Bioorg. Med. Chem. Lett., 20, 3150-3154, 2010.

Yang Zhao, Mao-Jung Lee, Connie Cheung, Ji-Hyeung Ju, Yu-Kuo Chen, Ba Liu, Longqin Hu, and Chung S. Yang,  Analysis of multiple metabolites of tocopherols and tocotrienols in mice and humans. J. Agric. Food Chem. 2010, 58(8), 4844–4852.

Belinda S. Hall, Xinghua Wu, Longqin Hu, and Shane R. Wilkinson, Exploiting the drug-activating properties of a novel trypanosomal nitroreductase. Antimicrob. Agents Chemother. 2010, 54(3), 1193-1199.

Professor Longqin Hu presented a seminar entitled “Design of Anticancer Prodrugs to Better Target Cancer Cells” at the College of Pharmacy, South Dakota State University, Brookings, SD, 03/19/2010.

  • Student Awards
  • Suzanne Rzuczek has been awarded the Bevier Fellowship for the 2010-2011 academic year. The fellowship is in memory of classicist, Louis Bevier Jr. (1857-1925), an 1878 graduate of Rutgers College and a Professor of Greek at Rutgers at the end of his career.

    Thomas Villani has been awarded a Celgene Fellowship in Drug Discovery for the 2010-2011 academic year from the Graduate School - New Brunswick. Mr. Villani earned a B.S. in Chemistry from Worchester Polytechnic Institute in Massachusetts.


    Professor Edmond LaVoie served on the search committee for the new Executive Director of the Office of Technology Commercialization.  He participated in the interviews of several candidates and provided recommendations to Dr. Michael Pazzani.  These efforts resulted in the successful recruitment of Dr. Dipanjan Nagas the Executive Director of the Office of Technology Commercialization.

    Professor Edmond LaVoie currently serves on the university committee on Harmonizing the Commercialization of Technology at Rutgers University which is chaired by Professor Patrick Sinko.
    Professor Edmond LaVoie served as a Member of the Scientific Committee for the American Association of Cancer Research and helped to establish the program for the Molecular Targets and Cancer Therapeutics meeting of AACR-EORTC held in Boston, MA this past November.
    Professor Edmond LaVoie was designated as an Expert Reviewer for the Swiss National Science Foundation (SNSF) for 2009-2010.
    00335.007 Series, Edmond .J. LaVoie, Joseph .R. Rice, and Suzanne Rzuczek,
    Therapeutic Compounds, US Provisional Patent Application filed November 6, 2009.

    Wei Feng, Mavurapu Satyanarayana, Angela A. Liu, Yuan-Chin Tsai, Leroy F. Liu, and Edmond J. LaVoie, 12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo-[i]phenanthridine derivatives as novel topoisomerase I-targeting antitumor agents, Bioorg. Med. Chem., 17, 2877-2885, 2009.
    Wei Feng, Mavurapu Satyanarayana, Angela A. Liu, Yuan-Chin Tsai, Leroy F. Liu, and Edmond J. LaVoie, Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H -2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[ c,h][1,6] naphthyridin-5-one, European J. Med. Chem. 44, 3433-3438, 2009.
    Lisa Sharma, Angela A. Liu, Yuan-Chin Tsai, Leroy F. Liu, and Edmond J. LaVoie, Evaluation of the Cytotoxicity and TOP1-Targeting Activity of 8-and 9-Amino Derivatives of 5-Butyl-5H-dibenzo[c,h][1,6]naphthyridin-6-one and 5-(2-N,N-Dimethyl-amino)ethyl-5H-dibenzo[c,h ][1,6]naphthyridin-6-one, Euro. J. of Med. Chem.,44, 1471-1476, 2009.
    Yuan-Chin Tsai, Haiyan Qi, Chao-Pao Lin, Edmond J. LaVoie, Joseph E. Rice, Daniel S. Pilch, and Leroy F. Liu, Induction of M Phase Arrest and Apoptosis by a Novel G-Quadruplex Stabilizer, J. Biol. Chem.,284, 22535-22543, 2009
    Mansooreh Jaberi-Pour, Simon Vass, Christopher P. Guise, Jane I. Grove, Richard Knox, Longqin Hu, Eva I. Hyde and Peter F. Searle,  Testing double mutants of the enzyme nitroreductase for enhanced cell sensitization to prodrugs: effects of combining beneficial single mutations. Biochem. Pharmacol.2010, 79(2), 102-111.

    LaVoie, E.J.; Kim, Y.A.; Satyanarayana, M.; Rzuczek, S.G.; Pilch, D.S.; Tsai, Y-C.; Qi, H.; Lin, C-P.; Liu, A.; Liu, L.F.; Rice, J.E. Oxazole-containing macrocycles as selective G-quadruplex stabilizers. Mol. Targets Cancer Therap. Proc., Nov. 2009, Boston, MA, 275. 
    Roth S., LaVoie E., O’Shea T., Fang, R., Kurtzberg L., Teicher, B.A., Schmid S.M., Krumbholz, R., Crawford J., Bormann, C., Dunham S., Genz-644282 a non-camptothecin topoisomerase one inhibitor demonstrates a wide spectrum of in vitro and in vivo activity. Mol. Targets Cancer Therap. Proc., Nov. 2009, Boston, MA, p. 321. Abstract nbr. C220.
    Kurtzberg L., Yao, M., Rouleau, C. Bagley, R.G., Yu, X-J. Wang, Fei, LaVoie, E.J., Teicher, B.A., Genz-644282 a novel non-camptothecin topoisomerase I inhibitor for cancer treatment Mol. Targets Cancer Therap. Proc., Nov. 2009, Boston, MA., p. 320.  Abstract nbr. C217.